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IL-la stimulated TNFa production by cultured human proximal
tubular epithelial cells. Tumor necrosis factor alpha (TNFa) production
by proximal tubuli was studied by immunoperoxidase staining of 20
renal biopsies from transplant patients. A positive staining for TNFa on
proximal tubuli was seen in nine out of 15 patients with interstitial
infiltrate, five without clinical significant rejection and four with mod-
erate to severe interstitial rejection. TNFa was only expressed on tubuli
within areas of interstitial infiltrate. Expression of TNFa in the mono-
nuclear cell infiltrate was seen only in three patients with interstitial
rejection. Absence of TNFa could be seen in biopsies with no renal
abnormalities. To obtain more information on the regulation of TNFa
production, proximal tubular epithelial cells (PTEC) cultures were
established and assessed for production of TNFa. Heterogenicity in
production of TNFa was found in 14 tested PTEC lines cultured under
serum free conditions. The presence of IL-la in the cultures induced a
time- and dose-dependent enhancement of TNFa production by PTEC.
Enhanced production of TNFa was not seen after stimulation with
other cytokines such as IL-2 or IFN gamma. Inhibition studies with
cycloheximide indicated de novo synthesis of TNFa. Western blot
analysis of supernatants of unstimulated and IL-la stimulated PTEC
indicated a 17 kd product, a size similar to that of recombinant TNFa.
Northern blot analysis revealed the presence of a 2.0 kb hybridization
signal in total RNA of PTEC cultures and up regulation upon treatment
of PTEC with 1 ng/ml of IL-la. These results show that TNFa is
produced by infiltrated mononuclear cells (MNC) and PTEC within
areas of interstitial infiltrate, and thus may modulate the immune
response during interstitial rejection.
Tumor necrosis factor alpha (TNFa) is a cytokine with
multiple biological activities such as chemotactic activity, pros-
taglandin release, synthesis of procoagulant factors, induction
of cytokines and up regulation of MHC and adhesion molecules
[1—71. Moreover, TNFa may function as a costimulatory factor
for T cells [8—10]. TNFa probably plays an important role in the
pathogenesis of various diseases [11—131. Recently, attention
has centered on the role of TNFs in allograft rejection.
In 1981 Moy and Rosenau reported the presence of a lym-
photoxin in rejecting human renal allografts [14]. Lowry and
Blais [151 first demonstrated the presence of TNFa in rejecting
rat cardiac allografts. The initial observation of elevated serum
levels of TNFa during acute rejection episodes in renal trans-
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plant recipients was made by Teppo and Maury [16] and was
shown also to occur in liver transplant recipients experiencing
acute rejection [171. The production of TNFa is normally tightly
regulated to avoid systemic toxic injury. Under pathological
conditions, however, dysregulation occurs and disproportion-
ate quantities of TNFa may be released systemically causing
major complications [3].
We have previously shown that proximal tubular epithelial
cells (PTEC) may function as a specific target during allograft
rejection [18, 19]. Since it has been shown that PTEC can be
induced to express MHC class II antigens and adhesion mole-
cules [2, 20, 21] PTEC may also be involved in antigen
presentation [2, 22, 23]. If PTEC play an accessory role in
antigen presentation, local production of costimulatory cyto-
kines is of importance to prevent clonal anergy [24]. In a recent
study by Wuthrich et al [2] it has been shown that transformed
murine tubular epithelial cells produce low levels of secreted
and membrane bound TNFa. These results prompted us to
examine whether TNFa is present in situ in renal biopsies, and
whether regulation of TNFa production by PTEC may take
place in vitro by cytokines.
Methods
Patients
In this study 20 patients who had received a renal allograft
(Table I) were studied for expression of TNFa in situ. The
patient's and recipient's age and sex, histological findings in the
biopsies, and time interval between transplantation and biopsy
are given in Table 1. Biopsies in patients ito 12 were performed
in patients with well functioning grafts in the context of a larger
study into the value of histological findings to diagnose rejec-
tion. Biopsies 13 to 20 were all done for clinical reasons. This
study was approved by the Medical Ethical Committee of the
University Hospital, Leiden, and informed consent was ob-
tained from all patients.
Antisera
Anti-TNFa and anti-IL-ia IgG were made by immunizing
rabbits with human recombinant TNFa and IL-la, respec-
tively, in Freund's complete adjuvant. Every 10 days the
immunized rabbits were boosted using incomplete adjuvant.
The specificity of the immune serum was determined by
ouchterlony. IgG was isolated from immune serum by 33%
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Table 1. Demographic data of patients and recipients
Sexa/aget Time interval between
transplantation and
biopsy Biopsy finding and renal function inf,'1
TNFa
tub.UPatient Recipient Donor
1 F/SO F/36 22 days no renal abnormalities, GFRC 53
2 M159 F/49 35 days slight interstitial infiltrate, GFR 47 — +
3 M/49 M164 6 days slight arteriosclerosis, GFR 35.5 — —
4 M/29 M/32 6 days no renal abnormalities, GFR 99 — —
5 F/55 M1l7 33 days no renal abnormalities, GFR 35 — —
6 M14l F/54 7 days slight interstitial infiltrate, GFR 4.4 — +
7 M141 F/20 7 days no renal abnormalities, GFR 39 — —
8 F/64 F/36 10 days light interstitial rejection, GFR 17 — +
9 M/40 F/57 9 days arteriosclerosis, GFR 36 — —
10 F/l7 F/32 7 days slight interstitial infiltrate, GFR 58 — +
11 F/42 M/57 8 days no renal abnormalities, GFR 56 — —
12 M/40 M/l9 25 days slight interstitial infiltrate, GFR 71 — +
13 M146 Ff59 3 months moderate to severe interstitial rejection, creatinine
clearance 22 mI/mm
— —
14 F/57 Ff58 1 week moderate interstitial rejection, creatinine clearance
2.5 mllmin
+ ND
15 F/32 F/35 2 months moderate interstitial rejection, creatinine clearance
24 mI/mm
+ +
16 Ff61 M/27 2 years moderate to severe interstitial rejection, creatiniñe
clearance 36 mi/mm
— +
17 F/S3 F/59 1 week severe interstitial rejection, creatinine clearance
30.4 mI/mm
+ —
18 F/48 7.5 weeks moderate to severe interstitial rejection, slight
vascular rejection, creatinine clearance 39 ml/
mm
— +
19 M/59 M/66 10 days mild interstitial rejection, severe vascular
rejection, creatinine clearance 0.3 mI/mm
— —
20 M/39 F/60 1 week moderate interstitial rejection, creatinine clearance
21 ml/min
— +
U Male (M); female (F)b Age in years
Glomerular filtration rate (GFR) mI/mm method described in ref. 39
d Expression in infiltrate
Expression on tubuli
(NH4)2S04 precipitation followed by anion exchange chroma-
tography on DEAE-Sephacel (Pharmacia LKB, Woerden, The
Netherlands).
Peroxidase staining of cryostat sections
Immunuperoxidase staining of 3 m thick sections of frozen
tissue were performed as described before [25]. Briefly, the
sections of tissue were cut and put on gelatinized glass slides
and air-dried. Following three wash steps with phosphate-
buffered saline (PBS) the sections were incubated for 30 min-
utes at room temperature with 50 l of anti-TNFa IgG. Normal
rabbit IgG was used as negative control. Following three
washes the sections were incubated for 30 minutes at room
temperature in 100 pi of horseradish peroxidase (HRP)-conju-
gated swine anti-rabbit IgG (Dako, Glostrup, Denmark). There-
after, wash steps were repeated three times and 5% 3-amino-9-
ethylcarbazol in acetate buffer (37 ml 0.2 M acetic acid, 88 ml
0.2 M Na acetate, 125 ml distilled water), together with H2O2
was added for five minutes, followed by counterstaining with
Mayer's hematoxylin.
Cell culture procedure
PTEC were obtained following the methods described by
Detrisac et al [26] and cultured in serum-free Dulbeco s modi-
fled Eagle's medium (DMEM)/Ham's Fl2 medium in a 1: 1 ratio
(Seromed Biochrom KG, Berlin, Germany). The medium was
supplemented with insulin (5 g/ml), transferrin (5 g/ml),
selenium (5 ng/ml), hydrocortisone (36 nglml), tri-iodothyroni-
nine (4 pg/mI) and epidermal growth factor (10 ng/ml) (all from
Sigma, St. Louis, Missouri, USA). Cells were grown on a
matrix of bovine collagen (Vitrogen; collagen corporation, Palo
Alto, California, USA) and FCS proteins. Characterization of
PTEC was performed using various monoclonal antibodies
(MoAb), directed against cytokeratin (RGE 53, Eurodiagnos-
tics, Apeldoorn, The Netherlands), epithelial membrane anti-
gen (EMA, Dako, Glostrup, Denmark) and four MoAb directed
against the adenosine-deaminase binding protein (ADBP), des-
ignated 1071, 1072, 1079 and 1080 (donated by Dr. Dinjens,
University Hospital, Maastricht). A stable expression of these
antigens was observed even after high passages [26].
IL-Ia stimulation
PTEC were seeded in 24 well plates (Costar, Cambridge,
Massachusetts, USA). When confluency was reached PTEC
were stimulated with various concentrations of IL-la depend-
ing on the experiments performed. Each well received 300 d of
IL-la containing medium or normal medium without IL-la.
Stimulation was routinely carried out for 18 hours, however, in
kinetic experiments with IL-i a various time intervals were
chosen. Supernatants were harvested and assessed for TNFa
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using a bioassay. Cells in each well were trypsinized and
counted to express the amount of TNFa per iO cells. Only
PTEC that had been passaged three or four times were used in
this study.
TNFcx L929 bioassay
TNFa activity in culture supernatants was determined in a
standard cytotoxicity assay using L929 mouse fibroblasts
(ATCC, Rockville, Maryland, USA) as has been described
previously [27]. Briefly, 2.5 x io L929 cells/mi were plated in
96-well flat bottom plates (Costar). Supernatants were added in
triplicate to wells containing an equal volume of DMEM with 1
sg/ml of actinomycin D. Plates were incubated for 18 to 24
hours at 37°C. Thereafter plates were washed with warm
phosphate buffered saline (PBS). Viable cells were stained with
Crystal violet for 15 minutes. After washing the plates 100 d of
1% SDS was added to each well. Optical densities were read on
a 96-well microtiter plate reader at 590 nm, Serial dilutions of
human recombinant TNFa (1.6 to 1660 pg/mI) were used to
produce a standard curve.
RNA preparation and Northern blot analysis
Total RNA was isolated from confluent monolayers of cul-
tured PTEC with a single-step acid guanidium isothiocyanate-
phenol-chloroform extraction [28]. An equal amount of total
RNA (25 tg) was loaded on a 1.2% agarose gel electrophoresed
under denaturating conditions and transferred onto nylon mem-
branes (ICN, East Hills, New York, USA). Blots were baked at
80°C to cross link RNA to the blot. Prehybridization was
performed using a mix of 5 x Denhardt's, 5 x SSC, 50 mM
NaH2PO4 (pH 6.5), 0.1% sodium dodecyl sulfate (SDS), 250
g/ml herring sperm DNA and 50% formamide, for two to four
hours at 42°C. A specific 820 kb cDNA encoding human TNFa
was isolated from pUC 19 (provided by Dr. P van der Elsen) by
piasmid digestion with Eco Ri. The probe was radiolabeled by
primer extension using random hexanucleotides [29]. Blots
were hybridized for 16 to 24 hours at 42°C. After washing twice
with 2 x SSC/0. 1% SDS at room temperature and twice with 0.1
x SSC/0.1% SDS at 50°C the blots were exposed to Kodak
X-AR film at —70°C for seven days.
Western blot analysis
Concentrated (500x) culture supernatants were loaded on a
15% SDS polyacryl amide gel and electrophoreses was per-
formed (100 V/SO mA). In each run human recombinant TNFa
and molecular weight markers were included. Total protein was
blotted, using a semidry transfer, on a nitrocellulose filter. The
blot was stained for TNFa using a polyclonal antibody raised
against TNFa followed by goat antirabbit IgG-biotin. After
incubation with streptavidin-alkaline phosphatase (Zymed Lab-
oratories, San Francisco, California, USA) enzymatic conver-
sion of the substrate naphthol and fast red) was started. Each
incubation lasted for one hour at room temperature and was
followed by extensive washing with PBS-O.5% Tween 20.
Results
Expression of TNFa on cryostat section of the kidney
In situ expression of TNFa was examined on cryostat sec-
tions of renal biopsies from transplanted patients (N = 20).
Demographic and clinical data are given in Table 1. Positive
staining for TNFa on proximal tubuli was observed on cryostat
sections of biopsies from both patients having severe interstitial
rejection and patients without clinical significant interstitial
rejection. However, TNFa was exclusively localized on prox-
imal tubuli within areas of interstitial infiltrate, although not all
tubuli were positive in these areas (Fig. 1). Positive staining for
TNFa in the mononuclear cell infiltrate was only seen in three
patients with interstitial rejection. In three other biopsies with
similar histological findings, TNFa could not be demonstrated.
All biopsies with no renal abnormalities were negative for
TNFa.
Production of TNFa by cultured PTEC
Since TNFa expression on proximal tubuli was exclusively
seen at sites of interstitial infiltration, the ability of cultured
PTEC to produce TNFa in response to cytokines was exam-
ined. TNFa production was assessed on 14 PTEC lines from
different donors. Heterogenicity in TNFa production was ob-
served with basal production reaching from 0 up to 390 pg/ml/
io cells. Attribution to TNFa production by contaminating
monocytes or macrophages could be ruled out, since staining of
the cell culture was completely negative with anti-CD 14 anti-
body, whereas it was positive for the epithelial membrane
antigen (EMA). Introduction of IL-la in a dose-dependent
fashion resulted in enhanced production of TNFa (Fig. 2, Table
2). The effect of IL-la could be completely abolished by
antibodies against recombinant IL-I a, whereas normal rabbit
serum had no effect. Because the L929 cell line was not
exclusively susceptible to TNFa, supernatants of both unstim-
ulated and IL- 1 a stimulated PTEC were treated with anti-TNFa
and subsequently assessed for TNFa activity. This antibody
fully inhibited reactivity of the supernatants in the L929 assay,
suggesting that TNFa was the main activity in the PTEC
supernatants causing cytotoxicity of the L929 cells. To find out
whether other cytokines such as IFN gamma and IL-2 were also
able to influence TNFa production by PTEC, cultures of PTEC
were stimulated in a dose dependent fashion with IL-2 (0 to 500
U/mi) or IFN gamma (0 to 300 U/mi). TNFa production by
PTEC was not influenced by these cytokines, even after a
longer duration of stimulation (up to 3 days). Similarly, LPS did
not influence TNFa production.
To determine whether enhanced production of TNFa was the
result of newly synthesized protein or release from intracellular
storages, protein synthesis was blocked by cycloheximide
treatment. PTEC cultures were treated with cycloheximide (5
,ug/ml) for 24 hours followed by IL-la stimulation. TNFa
production could no longer be demonstrated (Table 3, column
A). When cycioheximide was removed from the culture by
washing the cells, PTEC were again able to produce TNFa
(Table 3, columns B and C), showing that cycloheximide
treatment did not cause irreversible damage to the cells.
To obtain more insight into the time required for TNFa
production, PTEC cultures were performed in the presence or
absence of 1 ng/ml of IL-la. Supernatants were harvested at
various time intervals and assessed for TNFa production.
There was a time dependent increase of TNFa production,
already evident after four hours following introduction of IL-i a
into the culture (Fig. 3A). In another set of experiments the
necessity of the continued presence of IL-la for enhanced
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Fig. 1. Expression of TNFa on cryostat sections of renal biopsies from transplant patients with no renal abnormalities (a) or with severe
interstitial rejection (b). Original magnification: x 100. Positive staining is indicated by arrows.
TNFa production was examined. PTEC cultures were pre-
treated with or without IL-i a (1 ng/ml) for 18 hours, after which
TNFa production was measured. Supernatants were replaced
by fresh medium without IL-i a, and subsequently TNFa pro-
duction was assessed at various time intervals. These experi-
ments demonstrate that enhanced production of TNFa occurs
by pretreating PTEC with IL-i a; however, the level of produc-
tion was much lower as compared to the continuous presence of
IL-ia (Fig. 3B).
Western blot analysis
To determine the size of secreted TNFa Western blot anal-
ysis of concentrated supernatants of unstimulated and IL-i a
stimulated PTEC was performed. As a control, human recom-
binant TNFa was run in one lane. A prominent band of 17 kD
was detected in both unstimulated and IL-la stimulated PTEC
supernatant corresponding with the size of human recombinant
TNFa (Fig. 4).
mRNA production of TNFa by cultured PTEC
To detect mRNA specific for TNFa, Northern blot analysis
was performed. Total RNA from unstimulated and IL-la stim-
ulated PTEC was isolated and hybridized to a probe specific for
TNFa. There was a low, but detectable hybridization signal of
2.0 kb in unstimulated PTEC, which was up regulated upon
stimulation with IL-la (Fig. 5). Differences in intensity between
the two lanes were not due to an unequal amount of RNA
layered onto the gel, as could be observed on the agarose gel
stained with ethidium bromide.
1000
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Fig. 2. Effect of added IL-i a on the production of YNFa by PTEC.
Twenty four well plates containing l0 cells/well were exposed to IL-ia
and subsequently the supernatants were assessed for TNFa using a
bioassay as described in Methods. The results indicate the mean SD
(pg/mI/b5 cells) for triplicate determinations on the supernatants ob-
tained from two wells.
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Table 2. TNFa production by cultured human PTEC
PTEC
line
Basal
TNFa
production
TNFa production
after IL-I a
stimulation
1 66±25 816±110
2 88±20 1694±73
3 160±57 2126±104
4 128 104 1210 166
5 65±18 696±104
6 126±60 691±75
7 0 816±83
8 120±73 516±17
9 390 37 2424 425
10 0 636±100
11 120 33 579 156
12 0 230±47
13 0 436±16
14 153±16 233±50
Production of TNFa by different PTEC lines. io cells/well were
cultured in plain culture medium or IL-I a containing culture medium
for 18 hours. Supernatants were collected and assessed for TNFa as
described in the Methods section. Values represent the mean SD
(pg/mI/b5 cells) of triplicate determinations.
Discussion
TNFa is a multifunctional cytokine and an important media-
tor of immunologic and inflammatory processes. In animal
models of allograft rejection and autoimmune lupus nephritis
production of this cytokine is elevated [16, 17, 30]. Imagawa et
al [31] showed that anti-TNF antibody therapy prolongs al-
lograft survival in rats with acute rejection. In addition, the
administration of exogenous TNFa accelerates kidney damage
in NZB/W mice [32], although this could not be confirmed by
Jacob and McDevitt [33], production of TNFa by renal cells
could contribute to immune renal injury. In this study we
demonstrate that PTEC express TNFa in situ at sites of
mononuclear cell infiltrate after renal transplantation and that
cultured human PTEC can synthesize and secrete biologically
active TNFa.
Cultured human PTEC are heterogenous in their production
of TNFa and enhancement was always found upon stimulation
with IL- 1 a in a time- and dose-dependent fashion. Although
IL-la is known to be associated with membranes, it binds to the
same receptor as IL-1/3, therefore the effects induced by IL-I a
will be the same as for IL-l/3 [34]. Similar results have been
reported by Wuthrich et al [2] using murine tubular epithelial
cells that had been immortalized by SV4O transformation.
However, we could not confirm their report that enhanced
production of TNFa can be induced by LPS. The quantities of
TNFa produced by human untransformed PTEC in culture are
about 30-fold higher than in their culture system. Both the
transformation step and differences between species may un-
derlie the dissimilarities between their and our results. Hetero-
genicity in TNFa production by monocytes has been reported
by Bendtzen et al [35]. A negative correlation between HLA-
DR2 and TNFa production was found. We were not able to
look for statistical significance between HLA-DR2 expression
and TNFa production because of the limited number of tested
cell lines.
TNFa is produced by a variety of cells [3], however, acti-
vated monocytes and macrophages are the predominant pro-
ducers of this cytokine. Like monocytes, PTEC express con-
Table 3. Reversible inhibition of TNFa production by cycloheximide
Treatment A B C
Medium 54 21 70 8 not done
IL-la 1 ng/ml 790 54 not done 825 73
CyHx 5 g/m1 0 48 13 not done
CyHx and IL-la 0 not done 765 32
Column A: PTEC were cultured for 24 hours in the presence or
absence of cycloheximide (CyHx, 5 g/ml), and thereafter either were
or were not stimulated with IL-la (1 ng/ml) for 18 hours. Supernatants
were immediately harvested thereafter and assessed for TNFa produc-
tion. Columns B and C: After the procedure as described above was
completed, all media were removed by washing and replaced either by
plain culture medium (column B) or IL- 1 a containing culture medium
(column C). After another incubation of 18 hours, TNFa production in
the supernatants was assessed. Values represent the mean SD
(pg/mI/b5 cells) for triplicate determinations on supernatants from two
wells.
stitutive levels of TNFa mRNA. While in monocytes and
macrophages TNFa product is only secreted after stimulation
with IFN gamma, TNFa or IL-la, enhanced production of
TNFa by human PTEC could only be seen after stimulation
with IL-la. It is not likely that the inability to enhance TNFa
production by cytokines like IFN gamma or IL-2 is due to lack
of expression of these receptors. It has been shown that PTEC
can respond to IFN gamma by increased MHC class I cell
surface expression and induction of both MHC class II and
ICAM-1 expression [7, 20]. More recently we have shown [36]
that secretion of C3 by PTEC is enhanced by IL-2, suggesting
that functional IL-2 receptors are expressed by PTEC.
In humans TNFa has a subunit size of 17 kd and three
subunits combined noncovalently to form the active protein
[37]. The TNFa produced by PTEC in culture seems not to be
different from TNFa from other sources, since Western blot
analysis of concentrated supernatants of IL-la stimulated
PTEC revealed a specific band of 17 kd, showing that PTEC
synthesize TNFa with a normal molecular weight. Further-
more, Northern blot analysis showed a hybridization signal of
2.0 kb which has also been reported for the human cell lines
U937 and HL6O [38].
On cryostat sections of biopsies taken from renal transplant
patients we could demonstrate a strong positive staining for
TNFa on the proximal tubuli, at sites of mononuclear cell
infiltrate. Within these areas, however, not all tubuli were
positive for TNFa. This may reflect the local stimulation of
tubular cells by cytokines. Although we cannot exclude the
possibility that the presence of TNFa on proximal tubuli during
interstitial rejection is the result of absorption from the circu-
lation or the tubular lumen, our data clearly indicate that
cultured PTEC produce TNFa which can be up regulated by
IL-la. Since the presence of TNFa could only be demonstrated
within areas of mononuclear cell infiltrate, it is plausible that up
regulation of TNFa production by PTEC during rejection is the
result of local production of cytokines or the direct interaction
of leukocytes with PTEC. This study does not provide data to
specify the mechanisms involved in up regulation of TNFa
production in vivo.
In this study we demonstrate for the first time that TNFa is
produced in vitro by cultured human PTEC and in vivo is
present on proximal tubuli in both patients without and with
clinically significant interstitial rejection. In addition, we show
0 10 20 30 40
Time, hours
0
Fig. 3. Kinetics of TNFa production by PTEC. A. Two wells with PTEC monolayers (l0 cells/well) were incubated in the presence of IL-i a (1
ng/ml) (S) or in medium alone (0). At timed intervals culture supernatants were collected and assessed for TNFa. Values are the mean SD
(pg/mi/b5 cells) for triplicate determinations. B. Two wells with PTEC monolayers (l0 cells/well) were preincubated for 18 hours with IL-la (1
nglml) () or with medium alone (0). At T =0 supernatants were collected, assessed for TNFa and fresh medium without IL-la was added to
the cells. Thereafter at various time points supernatants were collected and tested for TNFa. Values represent the mean SD (pg/mi/b5 cells) for
triplicate determinations.
Fig. 4. Western blot analysis of the effect of IL-Ia stimulation. Human Fig. 5. Northern blot analysis of the effect of IL-Ia on the expression
recombinant TNFa (lane 1) or concentrated (500 x) supernatant of of TNFa mRNA by PTEC in culture. Cells were incubated in the
unstimulated (lane 2) and IL-la (1 ng/ml) stimulated PTEC (lane 3) were presence of IL-la (1 ng/ml) (+) or in medium along (—). After 24 hourstotal RNA was isolated and from each culture 25 g RNA wasblotted on nitrocellulose. TNFa was detected using a polyclonal
antibody against human recombinant TNFa as described in Methods. electrophoresed, blotted and hybridized. The upper panel shows hy-bridization to a human TNFa eDNA probe, whereas the lower panel
shows the 28S ribosomal band on the agarose gel stained with ethidium
bromide.
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that TNFa is also produced by infiltrated mononuclear cells
during interstitial rejection. These observations have important
clinical implications, since TNFa produced by PTEC may
amplify tissue damage directly and activate graft infiltrating T
cells during renal allograft rejection.
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